PRIVATE EQUITY
US$30 Million Series A Investment in Mirror Biologics
Oct 2022 · Venture Capital · Biotechnology
In October 2022, Bradbury Group completed the final US$20 million tranche of Mirror Biologics, Inc.’s US$30 million Series A round, having provided an initial US$10 million tranche in December 2021. Together, the two tranches represent Bradbury’s full backing of the round.
As part of the investment, Bradbury Group CEO Keith Loo joined Mirror Biologics’ Board of Directors. Loo said Bradbury remains “dedicated to continued support and long-term partnership” with the company.
The funding is allocated to support Mirror Biologics' clinical pipeline, specifically advancing its ongoing immunology and oncology clinical trials. Additionally, proceeds from the Series A round are directed toward the expansion of the company's commercial-scale biomanufacturing infrastructure and general corporate working capital.
This transaction aligns with Bradbury's strategic mandate of deploying capital into regulated, mid-to-late-stage life science and biopharma enterprises.
Source: Mirror Biologics, Inc. press release, October 2022.